QL315

QL315 is a preclinical-stage bispecific T-cell engager (bispecific antibody) designed to target leucine-rich repeat-containing protein 15 (LRRC15) and CD3. Developed by QLSF Biotherapeutics in collaboration with Qilu Pharmaceutical, QL315 is built on a silenced human IgG1 backbone to eliminate Fc gamma receptor-dependent functions. It is designed to recruit and redirect T cells to eliminate LRRC15-expressing tumor cells and tumor-associated fibroblasts (CAFs) in the tumor microenvironment. In preclinical studies, QL315 demonstrated robust, conditional T-cell activation and tumor cell lysis in vitro, as well as significant tumor regression in mouse xenograft models. However, the candidate has been removed from the active development pipeline.

Other names

QL315.T4QL-315.T4QL 315.T4QL315.T5QL-315.T5QL 315.T5